Testimony of Diana Zuckerman at the FDA Antimicrobial Drugs Advisory Committee Meeting on Sulopenem

September 9, 2024: NCHR's Dr. Diana Zuckerman tells FDA Advisory Committee that sulopenem antibiotic is not proven to benefit patients with uncomplicated UTI compared to amoxicillin or Cipro. It should be evaluated in terms of alleviating symptoms, not in terms of bacteria in the urine, and definitely should not be considered a first line treatment.

The post Testimony of Diana Zuckerman at the FDA Antimicrobial Drugs Advisory Committee Meeting on Sulopenem appeared first on National Center for Health Research.